| Document Date: 2004-01-06 18:55:54
Open Document File Size: 578,30 KBShare Result on Facebook
Company Postlethwaite AE / Adams Laboratories / Adams Labs / / Country Afghanistan / Canada / Iraq / / Event FDA Phase / Patent Issuance / / IndustryTerm immediate-release products / law change / false and misleading advertising / guaifenesin products / treatment of chronic disease / manufacturing rights / bi-layer technology / insurance coverage / manufacturing industry / sustained-release guaifenesin product / non-sugar based product / guaifenesin protocol / treatment of acute respiratory disease / recent law changes / sustained-release product / drug manufacturing industry / sustained-release guaifenesin products / justified removing all sustained-release guaifenesin products / / MedicalCondition acute respiratory disease / Fibromyalgia / bronchitis / lung disorders / A.I.D.S. Pneumonia / respiratory irritation / gout / fellow fibromyalgia sufferers / common lung infections / cystic fibrosis / chronic bronchitis / asthma / infertility / disease / Untreated disease / very serious diseases / diabetes / chronic lung disease / chronic disease / diseases / respiratory disease / / Organization Guai-Support / DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration / Congress / FDA / Department of Defense / / Person Curt Weldon Sally Burgess / Rick Santorum / R. Paul St. Amand / Arlen Specter / Kathleen Shuller / / Position attorney / attorney for further legal action / Representative Panama City FI / / Product Mucinex / Social Security System / industry / Guaifenesin syrup / guaifenesin / / Technology bi-layer technology / guaifenesin protocol / / URL http /
SocialTag |
December I, 2003 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [‘! cj 4 3 y-j; [ji:C 10 “\$J 133